Trial Outcomes & Findings for 3T MR Angiography of the Hepatic Vasculature (NCT NCT02299934)

NCT ID: NCT02299934

Last Updated: 2019-05-07

Results Overview

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

13 participants

Primary outcome timeframe

Day 1

Results posted on

2019-05-07

Participant Flow

Participant milestones

Participant milestones
Measure
Subjects Who Fulfill the Criteria for Living Liver Donation
Subjects who fulfill the criteria for living liver donation and are evaluated for the procedure with Computerized Tomography (CT) and Magnetic Resonance Imaging (MRI). Magnetic Resonance Imaging (MRI): MRI sequences for visualisation of the blood supply of liver without contrast agent. Compurtized Tomgraphy (CT): CT including CT Angiography (CTA) for the evaluation of hepatic vasculature.
Overall Study
STARTED
13
Overall Study
COMPLETED
0
Overall Study
NOT COMPLETED
13

Reasons for withdrawal

Reasons for withdrawal
Measure
Subjects Who Fulfill the Criteria for Living Liver Donation
Subjects who fulfill the criteria for living liver donation and are evaluated for the procedure with Computerized Tomography (CT) and Magnetic Resonance Imaging (MRI). Magnetic Resonance Imaging (MRI): MRI sequences for visualisation of the blood supply of liver without contrast agent. Compurtized Tomgraphy (CT): CT including CT Angiography (CTA) for the evaluation of hepatic vasculature.
Overall Study
Termination of study
13

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Subjects Who Fulfill the Criteria for Living Liver Donation
n=13 Participants
Subjects who fulfill the criteria for living liver donation and are evaluated for the procedure with Computerized Tomography (CT) and Magnetic Resonance Imaging (MRI). Magnetic Resonance Imaging (MRI): MRI sequences for visualisation of the blood supply of liver without contrast agent. Compurtized Tomgraphy (CT): CT including CT Angiography (CTA) for the evaluation of hepatic vasculature.
Age, Categorical
<=18 years
0 Participants
n=13 Participants
Age, Categorical
Between 18 and 65 years
13 Participants
n=13 Participants
Age, Categorical
>=65 years
0 Participants
n=13 Participants
Sex: Female, Male
Female
7 Participants
n=13 Participants
Sex: Female, Male
Male
6 Participants
n=13 Participants
Region of Enrollment
United States
13 participants
n=13 Participants

PRIMARY outcome

Timeframe: Day 1

Population: Study was terminated prior to collecting any outcome measure data.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Day 1

Population: Study was terminated prior to collecting any outcome measure data.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Day 1

Population: Study was terminated prior to collecting any outcome measure data.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Day 1

Population: Study was terminated prior to collecting any outcome measure data.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Day 1

Population: Study was terminated prior to collecting any outcome measure data.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Day 1

Population: Study was terminated prior to collecting any outcome measure data.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Day 1

Population: Study was terminated prior to collecting any outcome measure data.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Day 1

Population: Study was terminated prior to collecting any outcome measure data.

Outcome measures

Outcome data not reported

Adverse Events

Subjects Who Fulfill the Criteria for Living Liver Donation

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Samuel Chang

University of Colorado, Denver

Phone: 720-848-1875

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place